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doi:10.1016/j.jtcvs.2007.06.027bjective: Methicillin-resistant Staphylococcus aureus graft infection is one of the
ost serious complications of vascular surgery. Vancomycin is a potent antibiotic
gainst methicillin-resistant S aureus; however, systemic administration of vanco-
ycin is not very effective against methicillin-resistant S aureus graft infection.
herefore, we investigated whether a local sustained release of vancomycin prevents
ethicillin-resistant S aureus graft infection.
ethods: We have developed a poly-L-lactide-co-caprolactone sheet that enabled
ustained release of vancomycin for 2 weeks. An expanded polytetrafluoroethylene
ascular graft patch (1.5 mm2) was sutured at the anterior wall of the incised murine
bdominal aorta. Methicillin-resistant S aureus (1.0  103 colony-forming units)
as inoculated onto the graft surface. Thereafter, the graft was treated as follows (n
6 each): no treatment (control group), local injection of an aqueous solution of
ancomycin (vancomycin solution group) and local implantation of poly-L-lactide-
o-caprolactone containing vancomycin (vancomycin-PLCA group). After 7 days,
he graft and blood were sampled and cultured.
esults: The methicillin-resistant S aureus counts in the grafts of the vancomycin-
LCA group were significantly lower than those of the other groups. Blood cultures
f the vancomycin-PLCA group were all negative, whereas those of the other groups
ere all positive for infection. The survival rate in the vancomycin-PLCA group at
8 days was considerably higher than that in the control group (83.3% vs 16.7%).
onclusions: A local sustained-release sheet containing vancomycin reduced me-
hicillin-resistant S aureus counts in the infected vascular grafts, prevented sepsis,
nd drastically improved survival rates. This can be used as a highly effective and
ess-invasive adjunctive treatment method for preventing prosthetic methicillin-
esistant S aureus graft infection.
rosthetic vascular graft infection has been one of the most serious complica-
tions of vascular surgery. Although its incidence is relatively low, a high
mortality rate ranging from 12% to 75% has been reported.1-4 Methicillin-
esistant Staphylococcus aureus (MRSA) is one of the most common and serious
athogens isolated from patients with vascular graft infections.5,6 Thus, an effectiv
trategy to prevent MRSA graft infections is urgently required.
Typically, systemic administration of antibiotics, such as vancomycin or teico-
lanin, is used for treatment. However, it is often noted that this strategy is not
ompletely effective because the antibiotic concentration in the tissues around the
raft is considerably low.7 Furthermore, repeated systemic antibiotic administratio
ometimes induces serious side effects, such as renal damage.
The Journal of Thoracic and Cardiovascular Surgery ● Volume 135, Number 1 25
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2
A
CDThus, to prevent MRSA graft infection by means of a
ore effective strategy, we developed a local delivery sys-
em based on the local sustained release of vancomy8
his system maintains sufficient antibiotic concentration in
he tissues around the infected materials for a sufficient time
eriod without requiring repeated systemic vancomycin ad-
inistration. In the previous study we tested the effects of
he poly-L-lactide-co-caprolactone (PLCA) sheet system in
he subcutaneous graft–infected models. The animal model,
owever, does not completely simulate the clinical situa-
ions of vascular graft infections: thus, we developed a
urine model of vascular graft infection of the abdominal
orta in the present study and investigated the effects of the
ancomycin sheet in preventing vascular graft infections of
he abdominal aorta.
aterials and Methods
reparation of a PLCA Sheet Containing Vancomycin
e used PLCA9,10 as a sustained-release carrier for vancomyc
he PLCA was purchased from BMG Co, Ltd (Kyoto, Japan). The
LCA was hydrolyzed in vivo and is absorbed over time. The
LCA sheet containing vancomycin was prepared as reported
reviously.8 In brief, an aqueous phase consisting of vancomy
20.0 mg) in 0.45 mL of double-distilled water was prepared. The
queous phase was then added into 4.05 mL of 1,4-dioxane con-
aining 103.5 mg of PLCA and agitated with a vortex mixer,
omogenizer, and an ultrasonic generator. The solution was placed
nto a round glass dish (8.4 cm2) and lyophilized to make the sheet
2-mm thickness). The sheet was cut into 4 sectors (2.1 cm2 each,
-mm thickness). As a result, one sector contained 5.0 mg of
ancomycin. All the procedures were conducted under sterile
onditions.
reparation of MRSA
he MRSA strain SR3737 was used as the infecting organism.
RSA was supplied by Sionogi Co, Ltd (Osaka, Japan). In this
tudy a concentration of 1.0  104 cells/mL was used for graft
noculation.
nimals
ale Wistar rats (body weight, 300–350 g) were purchased from
apan SLC (Shizuoka, Japan). All animals were cared for in
ompliance with the “Guide for the care and use of laboratory
nimals,” Institute of Laboratory Animal Resources, Commission
n Life Sciences, National Research Council. All of the assess-
ents were performed by investigators who were blinded to the
Abbreviations and Acronyms
CFU  colony-forming units
MIC minimum inhibitory concentration
MRSAmethicillin-resistant Staphylococcus aureus
PLCA  poly-L-lactide-co-caprolactonerouping of the study rats. s
6 The Journal of Thoracic and Cardiovascular Surgery ● Januatudy 1: Release Profile of Vancomycin From the
LCA Sheet and Tissue Concentration of Vancomycin
round the Sheet in the Retroperitoneal Space
tudy groups. Forty-eight rats were intraperitoneally anesthetized
ith sodium pentobarbital (50 mg/kg). The retroperitoneal space
as approached transperitoneally through a midabdominal inci-
ion. The animals were divided into 2 groups: the vancomycin–
LCA group and the vancomycin solution group (n 24 each). In
he vancomycin-PLCA group, after incision of the retroperito-
eum, a vancomycin-PLCA sheet (2.1 cm2 each, 2 mm-thickness)
ontaining 5.0 mg of vancomycin was placed on the abdominal
orta, and the retroperitoneum was closed with suturing. In the
ancomycin solution group an aqueous solution containing the
ame amount (5.0 mg) of vancomycin that was dissolved in 0.5 mL
f physiologic saline was sprayed on the abdominal aorta, and the
etroperitoneum was closed with suturing.
Tissue collection and vancomycin measurement. On days 1, 2,
, 7, 10, and 14 after implantation, 4 rats per group were killed
ith an intraperitoneal administration of a lethal dose of sodium
entobarbital, and the remaining vancomycin-PLCA sheet and the
issue around the sheet were immediately harvested. Blood sam-
les were simultaneously collected for measuring the blood van-
omycin concentration. The vancomycin remaining in the har-
ested vancomycin-PLCA sheet was extracted into an organic
olvent (dichloromethane), and the precipitant was dissolved in
hysiologic saline. The amount of vancomycin released was mea-
ured by using the fluorescence polarization immunoassay.
The tissue around the vancomycin-PLCA sheet was collected
rom a 20  20–mm square that included the abdominal aorta,
nferior vena cava, psoas muscle, and retroperitoneum. The tissue
round the vancomycin-PLCA sheet was weighed and subse-
uently homogenized with 5 mL of phosphate-buffered saline
olution at 15,000 rpm for 15 minutes in a blender. The emulsion
as then centrifuged at 5000 rpm for 15 minutes, and the amount
f vancomycin in the supernatant fluid was measured by means of
uorescence polarization immunoassay. Tissue concentration was
etermined as the ratio of vancomycin to the volume of phosphate-
uffered saline for the same weight of tissue (in micrograms per
illiliter).
tudy 2: Prevention of Graft Infection of the
bdominal Aorta on MRSA Inoculation
atch-suturing model. After the aorta was crossclamped above
nd below the patch-suturing region, the anterior region of the
ortic wall was incised 1 cm distal to the right renal artery and a
.5 1.0–mm expanded polytetrafluoroethylene graft was sutured
n it by using 8-0 polypropylene sutures (Figure 1). There
RSA (1.0  103 colony-forming units [CFU]) was inoculated
nto the graft surface. The volume of bacterial suspension was set
o 0.1 mL. The retroperitoneum was closed with a 6-0 polypro-
ylene suture. Heparin was not administered during the operation,
nd systemic antibiotics were not administered during the opera-
ion or in the perioperative period.
Study groups. The animals were divided into the following 3
roups (n  6 in each cases): a control group wherein MRSA
lone was inoculated onto the graft surface; a vancomycin solution
roup that was administered a local bolus injection of an aqueous
olution of vancomycin (5.0 mg) onto the graft surface after 5
ry 2008
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A
CDinutes of MRSA inoculation; and a vancomycin-PLCA group
herein a vancomycin-PLCA sheet (5.0 mg) was implanted onto
he graft surface after 5 minutes of MRSA inoculation.
Evaluation of bacterial colonization (CFU assay). The rats
rom all 3 groups were killed 7 days after the operation. Macro-
copic findings of prosthetic graft infection were noted, and all
rafts were carefully explanted under sterile surgical conditions.
rterial blood samples were collected for culturing. MRSA cells in
he explanted grafts and in the arterial blood were counted as
reviously described.8
tudy 3: Survival Study
welve patch-sutured models were made in the same maneuver,
nd the animals were divided into the following 2 groups (n  6
n each cases): a control group wherein MRSA (1.0  103 CFU)
lone was inoculated onto the graft surface and a vancomycin-
LCA group wherein a vancomycin-PLCA sheet (5.0 mg) was
mplanted onto the graft surface after 5 minutes of MRSA (1.0 
03 CFU) inoculation. Thereafter, we observed survival for 4
eeks.
tatistical Analysis
he experimental results have been expressed as the mean 
tandard deviation. For multiple comparisons among independent
roups in which analysis of variance indicated significant differ-
nces, the statistical value was determined by using the Bonferroni
r Dunn methods. Differences between the groups were deter-
ined by using the unpaired Student t test. Cumulative survival
urves were constructed by using the Kaplan–Meier method. The
og-rank test was used to compare survival curves. Statview soft-
are (Statview Corp, Cary, NC) was used for all statisticalnalyses. b
The Journal of Thoracesults
tudy 1
elease profile of vancomycin from the PLCA sheet in the
etroperitoneal space. The percentage of vancomycin re-
aining in the harvested sheet was 53.1%  12.5%, 29.4%
12.3%, 16.7%  8.0%, 11.9%  7.6%, 8.8%  4.5%,
nd 6.3%  4.5% on days 1, 2, 4, 7, 10, and 14, respec-
ively. Thus the vancomycin-PLCA sheet released vanco-
ycin for more than 2 weeks (Figure 2).
Tissue concentration of vancomycin around the sheet
n the retroperitoneal space. The tissue concentrations in the
ancomycin–PLCA group were 16.3  8.6, 13.0  10.3, 3.0
1.4, 6.8  3.7, 4.7  3.7, and 5.8  2.4 g/mL on days 1,
, 4, 7, 10, and 14, respectively. In contrast, the tissue concen-
ration of vancomycin in the vancomycin solution group was
.1  6.9 g/mL on day 1, and on day 2, this concentration
ecreased to 0.4  0.4 g/mL, which was less than the
inimum inhibitory concentration (MIC) of vancomycin
gainst MRSA (2.0 g/mL). In addition, the concentration on
ays 4, 7, 10, and 14 was less than the detectable limit in all
ases (0.2 g/mL). The vancomycin solution dissipated rap-
dly; however, the vancomycin-PLCA sheet maintained the
issue concentration higher than the MIC of vancomycin
gainst MRSA for 2 weeks (Figure 3).
Blood vancomycin concentration. The blood vancomy-
in concentration at all instances was less than the detection
imit (0.2 g/mL) in the vancomycin-PLCA group. Local
mplantation of vancomycin-PLCA did not increase the
Figure 1. Graft patch-suturing model. A 1.5 
1.0 –mm expanded polytetrafluoroethylene (e-
PTFE) graft was sutured on the incised abdomi-
nal aorta by using 8-0 polypropylene sutures.lood vancomycin concentration.
ic and Cardiovascular Surgery ● Volume 135, Number 1 27
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2
A
CDtudy 2
acroscopic findings of the periprosthetic graft. Seven
ays after the implantation of the prosthetic graft, superficial
ound abscesses were not observed in all groups. The
acroscopic findings of the periprosthetic graft are listed in
able 1. In the control group all rats showed periprost
bscesses and purulent fluid accumulation; however, the
ancomycin-PLCA group showed no infection (Figure 
MRSA cell count in the implanted graft and arterial
lood (CFU assay). In this study no colonization of other
ndogenous bacteria in implanted grafts was detected in
ll cases. Figure 5 shows the cell count of MRSA 
mplanted graft and the arterial blood. The MRSA counts
n the grafts of the control, vancomycin solution, and
ancomycin-PLCA groups were 7.2  5.6  107, 1.6 
.2  107, and 7.9  10.5  104 CFU/mL, respectively.
hus the vancomycin-PLCA sheet drastically reduced the
acterial colonization in the graft by 3 orders of magni-
ude compared with administration of vancomycin solu-
ion. The MRSA counts in the blood of the control or
ancomycin solution groups were 104 to 105 CFU/mL,
hereas those of the vancomycin-PLCA group were not
bserved. The results suggested that the vancomycin–
LCA sheet can limit bacterial spreading from the local
raft site into the systemic circulation.
tudy 3
or survival data, see Figure 6. The survival curves 
ignificantly different between the groups (P  .05). The
urvival rates at 28 days were 16.7% in the control group
nd 83.7% in the vancomycin-PLCA group. In the control
igure 2. Release profile of vancomycin (VCM) from the poly-L-
actide-co-caprolactone (PLCA) sheet in the retroperitoneal
pace. The x-axis shows the time course, and the y-axis shows
he percentage of vancomycin remaining in the harvested sheet.
he vancomycin-PLCA sheet released vancomycin for more than
weeks in the retroperitoneal space.roup 2 rats died suddenly on days 7 and 15 after the a
8 The Journal of Thoracic and Cardiovascular Surgery ● Januae
peration because of rupture of the anastomotic site, and 3
ats died on days 5, 13, and 15 after the operation because
f sepsis. In the vancomycin-PLCA group only 1 rat died on
ay 14 after the operation of unknown reasons.
iscussion
rincipal Findings
he most noteworthy finding was that the vancomycin-
LCA sheet prevented sepsis in MRSA graft infection of
he abdominal aorta and drastically improved survival rates.
RSA counts in the grafts of the vancomycin-PLCA group
ere considerably lower than those of the other groups. The
esults suggest that the vancomycin-PLCA sheet has great
otential in preventing MRSA graft infections.
rosthetic Graft Infection Model of the Abdominal
orta
o the best of our knowledge, this is the first report that
emonstrates an in situ murine prosthetic vascular graft
nfection model. Although a simple model of subcutaneous
raft infection has been widely used for prosthetic graft
nfection,11-14 the model did not completely simulate 
linical situation because of the lack of exposure to the
lood flow. In our previous study using the murine subcu-
aneous graft infection model, sepsis and death caused by
RSA infection were not observed in any of the ca8
igure 3. Tissue concentration of vancomycin (VCM) around the
heet in the retroperitoneal space. The x-axis shows the time
ourse, and the y-axis shows the concentration of vancomycin (in
icrograms per milliliter). The vancomycin–poly-L-lactide-co-ca-
rolactone (PLCA) group (closed circle, solid line) indicates im-
lantation of a vancomycin-PLCA sheet. The vancomycin solution
roup (open circle, dotted lines) indicates local injection of an
queous solution of vancomycin. The tissue concentration of
ancomycin-PLCA was maintained to a concentration higher than
he minimum inhibitory concentration (MIC) of methicillin-resis-
ant Staphylococcus aureus for 2 weeks. On the other hand, the
ancomycin solution concentration was maintained at greater
han the MIC only for 1 day.lthough death caused by sepsis or rupture of the anasto-
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A
CDotic site was observed in the present study. Therefore this
ife-threatening course of the model might simulate MRSA
raft infection in the clinical setting.
In the present study we used less MRSA and higher
oses of vancomycin than those of our previous study with
subcutaneous infection model. The reasons were as fol-
ows. In the pilot study with a retroperitoneal infection
odel, all rats died within 5 days when 1.0  104 CFU of
RSA or more was inoculated onto the graft surface.
herefore we used 1.0  103 CFU of MRSA in the present
tudy. We initially used 2.38 mg of vancomycin, as used in
he subcutaneous model; however, the effectiveness was
nsufficient. Therefore we used 5.0 mg of vancomycin. This
ight attribute to the difference between the subcutaneous
pace and retroperitoneal space that has abundant lymphat-
cs or peritoneal fluid. It might be important to select dif-
erent dosing schemes in each clinical situation.
RSA and Graft Infection
lthough recent studies have reported that MRSA is the most
ommon and serious infectious agent isolated in vascular graft
nfections,5,6 no effective strategies to prevent or treat MR
raft infections have been established to date. There have been
nimal studies on graft infection by using MRSA, and most of
hem used the subcutaneous graft infection model. Although
he use of in situ rifampicin-gelatin grafts has been used as a
able 1. Macroscopic findings at the surgical site on day
Control g
eriprosthetic abscess 6/6
onpurulent periprosthetic fluid collection 0/6
urulent periprosthetic fluid collection 6/6
 6 in all groups. In the control group all the rats showed periprosthet
roup showed no signs of infection. PLCA, poly-l-lactide-co-caprolactoneThe Journal of Thoracreventive measure against MRSA infection, it was not effec-
ive.15 To date, the use of these grafts is common in c
ereplacement of infected prosthetic grafts; however, these
esults suggested that the rifampicin-gelatin grafts were inef-
cient against MRSA infection.16
alidity of the Sustained Release of Antibiotics in
reventing Graft Infection
ancomycin was gradually released from the vancomycin-
LCA sheet for more than 2 weeks in the retroperitoneal
paces of rats, and the tissue concentration around the
heet was maintained at a concentration higher than the
IC of MRSA. On the other hand, in the solution form
f the same dose, the vancomycin concentration was
aintained at greater than the MIC only for 1 day.
urthermore, the serum vancomycin concentration was
ess than the detection limit (0.2 g/mL) in the vanco-
ycin-PLCA group. These results suggest that in addi-
ion to being effective at preventing MRSA infection, a
ingle local implantation of the vancomycin-PLCA sheet
ight also prevent systemic side effects. In addition, the
ancomycin-PLCA sheet is pliable, easy to handle, and
an be placed at any targeted site without a complicated
aneuver and can therefore be used under various infec-
ious conditions.
Figure 4. Macroscopic findings of the surgical
site on day 7 after the operation. A, Control
group: periprosthetic abscess and purulent fluid
accumulation were observed. B, Vancomycin–
poly-L-lactide-co-caprolactone (VCM-PLCA) group:
no infection was observed.
ter surgical intervention
Vancomycin solution
group
Vancomycin-PLCA
group
5/6 0/6
1/6 2/6
5/6 0/6
cesses and purulent fluid accumulation; however, the vancomycin-PLCA7 af
roup
ic absic and Cardiovascular Surgery ● Volume 135, Number 1 29
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3
A
CDAlthough the macroscopic findings of the vancomycin-
LCA group did not indicate infection, MRSA cells were
bserved in the removed grafts on days 7 and 28 of cultur-
ng. However, the macroscopic findings showed no signs of
nfection; pus, dead space, and effusions were not observed.
herefore we can conclude that MRSA graft infection was
Figure 5. Cell counts of methicillin-resistant Staphylo
blood. The y-axis shows the cell count of MRSA (logar
count in the graft. B, The MRSA cell count in the
vancomycin–poly-L-lactide-co-caprolactone (VCM-PLC
groups. Blood cultures of the VCM-PLCA group were
positive for MRSA infection.
igure 6. Cumulative survival curve of rats in the control and
ancomycin–poly-L-lactide-co-caprolactone (VCM-PLCA) groups.
he x-axis shows the days from the operation, and the y-axis
hows the survival rate. VCM sheet group, closed circle, solid
ine; control group, open circle, dotted lines. The survival curves
ere significantly different between the groups (P < .05). The
urvival rates at 28 days were 16.7% in the control group andr3.7% in the VCM-PLCA group.
0 The Journal of Thoracic and Cardiovascular Surgery ● Januaventually prevented, and the possibility of recurrence can
e considerably low.
linical Relevance
he vancomycin-PLCA sheet can be used in the prevention
nd adjunctive treatment of graft infection. Conventionally,
rosthetic graft infection has been treated by means of the
emoval of the infected graft, followed by extra-anatomic
ypass17,18 or anatomic reconstruction.16,19 If the infected gra
annot be removed, a muscle flap20 or omentum21 is used.
owever, these strategies alone cannot completely treat graft
nfection because of their insufficient bactericidal effects.
herefore a therapy combining the use of the vancomycin-
LCA sheet and the abovementioned procedures might im-
rove the results of graft infection treatment.
imitations
he current study has some limitations. First, we used rats
s our experimental model, which might be more resistant to
nfection than human subjects. Second, the animals were
nly followed up for a period of 4 weeks, and therefore the
ong-term results are unknown. Further investigations are
equired, including a larger animal model and results ob-
ained over a longer time period. Third, we did not use a
ontrol group that had daily intravenous administration of
ancomycin because intravenous administration has been
us aureus (MRSA) in the implanted graft and arterial
c scale). CFU, Colony-forming units. A, The MRSA cell
erial blood. The MRSA counts in the graft of the
oup were considerably lower than those of the other
egative, whereas those of the other groups were allcocc
ithmi
art
A) gr
all neported to be ineffective in graft infection. Fourth, the
ry 2008
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A
CDptimal release period of vancomycin was unclear. Further
tudy with various release periods of vancomycin is
ecessary.
onclusions
local sustained-release drug (vancomycin) delivery sys-
em showed reduced MRSA counts in the infected vascular
rafts, prevented sepsis, and drastically improved survival
ates without increasing the blood vancomycin levels. This
ystem can be used as a more effective and less-invasive
djuvant in the prevention of prosthetic MRSA graft
nfection.
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